A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety,
tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination
with balstilimab in participants with advanced refractory microsatellite stable colorectal
cancer without liver metastases.